Related Experiment Videos
Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1
Liu Ye1, Yi-Lin Li, Karin Mellström
1Karo Bio AB, Novum, Huddinge S-141 57, Sweden.
Journal of Medicinal Chemistry
|April 18, 2003
Summary
Novel thyroid hormone receptor (TR) ligands selective for TRbeta(1) offer potential therapeutic benefits for obesity and hyperlipidemia without cardiovascular toxicity. These TRbeta(1)-selective compounds demonstrate a significant therapeutic window in preclinical models.
Area of Science:
- Endocrinology and Pharmacology
- Molecular Biology and Structural Biology
Background:
- Thyroid hormones (T4 and T3) regulate critical physiological processes, including metabolism, growth, and cardiovascular function.
- Thyroid hormone receptor alpha 1 (TRalpha(1)) primarily mediates cardiac effects, while TRbeta(1) influences metabolic actions.
- Existing therapies using thyroid hormone analogs are limited by cardiovascular toxicity and hyperthyroid side effects.
Purpose of the Study:
- To synthesize and evaluate novel thyroid hormone receptor (TR) ligands with selectivity for the TRbeta(1) isoform.
- To assess the therapeutic potential of TRbeta(1)-selective ligands for metabolic disorders while minimizing cardiotoxicity.
- To elucidate the structural basis for TRbeta(1) selectivity.
Main Methods:
- Synthesis of homologous R(1)-substituted carboxylic acid derivatives as TR ligands.
- Radioreceptor binding assays and reporter cell assays to determine affinity and selectivity for TRalpha(1) and TRbeta(1).
- In vivo studies in a cholesterol-fed rat model to evaluate effects on heart rate, cholesterol levels, and TSH.
- X-ray crystallography to determine the structures of TRalpha and TRbeta ligand-binding domains complexed with a selective ligand.
Main Results:
- Acetic acid substitution at the R(1) position yielded the highest TRbeta(1) selectivity.
- Compounds 11a and 15 demonstrated significant TRbeta(1) selectivity in vitro and retained cholesterol-lowering potency in vivo.
- TRbeta(1)-selective compounds 11a and 15 showed significantly reduced heart rate effects compared to non-selective compounds, establishing a ~10-fold therapeutic window.
- X-ray crystallography revealed that a single amino acid difference in the ligand-binding pocket underlies the observed beta-selectivity.
Conclusions:
- Novel TRbeta(1)-selective ligands were developed with promising therapeutic potential for hyperlipidemia and obesity.
- These TRbeta(1)-selective compounds offer a favorable therapeutic window by decoupling cholesterol-lowering effects from cardiotoxicity.
- Structural insights confirm the molecular basis for TRbeta(1) selectivity, paving the way for safer thyroid hormone-based therapies.